Fairfax, Benjamin P. http://orcid.org/0000-0001-7413-5002
Taylor, Chelsea A.
Watson, Robert A.
Nassiri, Isar
Danielli, Sara
Fang, Hai http://orcid.org/0000-0003-3961-8572
Mahé, Elise A.
Cooper, Rosalin
Woodcock, Victoria http://orcid.org/0000-0001-7656-728X
Traill, Zoe
Al-Mossawi, M. Hussein http://orcid.org/0000-0002-2312-3754
Knight, Julian C. http://orcid.org/0000-0002-0377-5536
Klenerman, Paul
Payne, Miranda
Middleton, Mark R. http://orcid.org/0000-0003-0167-1685
Funding for this research was provided by:
Wellcome Trust ([201488/Z/16/Z])
Balliol Jowett Society
Cancer Research UK (C64881/A26189, C2195/A19716)
Wellcome Trust ([201488/Z/16/Z], [201488/Z/16/Z], WT109965MA)
NIHR Oxford Biomedical Research Centre
Article History
Received: 29 October 2019
Accepted: 9 December 2019
First Online: 10 February 2020
Competing interests
: M.H.M. reports personal fees from Amgen, grants and personal fees from Roche, grants from Astrazeneca, grants and personal fees from GSK, personal fees and other from Novartis, other from Millenium, personal fees, non-financial support and other from Immunocore, personal fees and other from BMS, personal fees and other from Eisai, other from Pfizer, personal fees, non-financial support and other from Merck/MSD, personal fees and other from Rigontec (acquired by MSD), other from Regeneron, personal fees from BiolineRx, personal fees and other from Array Biopharma (now Pfizer), non-financial support and other from Replimune, outside the submitted work. M.P. has received support with conference travel, and fees for advisory work and speaking from Amgen, BMS, L'Oreal, MSD, Novartis and Pierre Fabre. B.P.F. received support with conference travel from BMS.